NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
The Chinese name of NMNH is "reduced nicotinamide mononucleotide". NMNH is an amorphous yellow powder. NMNH increases NAD+ levels faster and at a higher concentration, on average 5 times that of NMN. NMNH has been industrialized and has a purity of ≥99%. It is available in two forms: free acid and sodium salt.
1. Introduction Nicotinamide adenine dinucleotide (NAD) has been unveiled to be essential for embryonic development. Patients with genetic variants in the NAD+ de novo synthesis pathway often have congenital NAD deficiency disorder (CNDD), a multisystem condition inherited in an autosomal recessive manner. In the context of NAD+ deficiency, all organs and systems, not just vertebrae, heart, kidneys, and limbs, may be affected. 2. The association between NAD synthetase 1 (NADSYN1) and CNDD Individuals delivering biallelic NADSYN1 variants share similar clinical features to those with CNDD. Up till now, almost all of the identified CNDD cases can be attributed to biallelic loss-of-function variants in any of 3 nonredundant genes of the NAD de novo synthesis pathway, including kynureninase (KYNU), 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), or NADSYN1. Among individuals with CNDD identified to date, those with biallelic pathogenic NADSYN1 variants are the most diverse in phenotype. 3. The impact of NADSYN1 variants upon enzymatic activity and phenotype Specifically, NADSYN1 can catalyse the amidation of nicotinic acid adenine dinucleotide (NaAD) to NAD. Biallelic pathogenic variants in NADSYN1 cause a metabolic block in both the de novo pathway and the Preiss-Handler pathway, leading to NAD deficiency. Biallelic NADSYN1 loss-of-function variants impact the NAD metabolome of humans. Post-birth phenotypes involve feeding difficulties, developmental delay, short stature, etc. 4. Mouse embryogenesis disrupted by the loss of NADSYN1 In NADSYN1-/- mouse embryos, NAD-dependent malformations occur when maternal dietary NAD precursors are limited during gestation. The affected Nadsyn1-/- embryos most frequently present malformations of the kidneys, eyes, and lungs. 5. The preventative effect of amidated NAD precursor supplementation against CNDD NADSYN1-dependent embryo loss and malformation in mice are preventable by dietary supplementation of amidated NAD precursors (NMN and NAM) during pregnancy. Maternal diet–derived NAD precursors primarily determine the development of healthy embryos. 6. Conclusion NAD-boosting supplements are essential for individuals with biallelic loss-of-function variants in NADSYN1. Maternal NAD precursor supplementation, to some extent, can reduce the risk of developing CNDD. Reference Szot JO, Cuny H, Martin EM, et al. A metabolic signature for NADSYN1-dependent congenital NAD deficiency disorder. J Clin Invest. 2024;134(4):e174824. Published 2024 Feb 15. doi:10.1172/JCI174824 About BONTAC BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and its precursors (eg. NMN and NR), with various forms to be selected (eg. endoxin-free IVD-grade NAD, Na-free or Na-containing NAD; NR-CL or NR-Malate). High quality and stable supply of products can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Nmnh, also known as nicotinamide mononucleotide hydrate, is a vital coenzyme found in all living cells. It plays a crucial role in cellular metabolism, energy production, and various biosynthetic processes. High purity Nmnh powder, being a pure and concentrated form of this coenzyme, is essential for various biochemical applications. 1. Energy Production Nmnh is a key component in the mitochondrial nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway. NAD+ is essential for the Krebs cycle, which is responsible for the production of adenosine triphosphate (ATP), the cellular energy currency. High purity Nmnh powder, when introduced into cellular systems, can enhance NAD+ levels, thus boosting energy production. 2. Cellular Metabolism Nmnh is involved in numerous metabolic reactions, including amino acid metabolism, lipid metabolism, and glucose metabolism. The presence of high purity Nmnh powder can promote these reactions, ensuring efficient nutrient utilization and waste removal. 3. Biosynthetic Processes Nmnh also plays a role in biosynthetic processes, such as the synthesis of nucleic acids and proteins. By providing adequate amounts of Nmnh, these biosynthetic processes can occur more efficiently, leading to increased cellular growth and repair. 4. Antioxidant Activity Nmnh exhibits antioxidant properties, protecting cells from oxidative stress and damage caused by reactive oxygen species (ROS). High purity Nmnh powder, with its concentrated levels of Nmnh, can effectively scavenge ROS, maintaining cellular health and integrity. 5. Therapeutic Applications Due to its diverse biological functions, high purity Nmnh powder has therapeutic potential in various diseases. It has been studied for its potential in treating neurodegenerative diseases, metabolic disorders, and aging-related conditions. The pure form of Nmnh ensures maximum bioavailability and efficacy in these applications. High purity Nmnh powder coenzyme plays a pivotal role in various biochemical processes, including energy production, cellular metabolism, biosynthetic processes, antioxidant activity, and therapeutic applications. Its pure and concentrated form ensures maximum biological activity and efficacy, making it a valuable addition to biochemical research and therapeutic interventions.
On April 24th-25th 2024, Health Food Expo, Ingredients and Contract Manufacture 2024 will be held in Tokyo International Exhibition Hall, Japan. Dr Cheung, the chief scientist and founder of BONTAC, is invited to deliver a speech themed by Independent Wholechain Technology for Coenzyme Synthesis at this exhibition. BONTAC will display patent-grade raw materials for enzymes and natural products at Booth No. A15. See you there for more surprises! About Dr. Cheung Dr Cheung, the chief scientist and founder of BONTAC, was once engaged in research work at the Institute of Genetics and Developmental Biology in Chinese Academy of Sciences, Cornell University and City University of Hong Kong. She has been dedicated to the application of biological enzyme catalysis technology into the green bio-manufacturing industrialization of coenzymes, medical intermediates and natural products for over 20 years. Notably, Dr. Cheung has applied approximately 90 invention patents at home and abroad, authorized over 60 patents and conducted key R&D plan projects in Guangdong province as well as key science and technology projects in Shenzhen city. BONTAC Product List Niche Area Products Application Scope NMN (CAS No.: 1094-61-7) Healthcare products; Cosmetics; Medicine NAD (CAS No.: 53-84-9) Healthcare products; Cosmetics; Diagnostic reagents Raw materials for enzyme catalysis; Animal health Coenzyme Endotoxin-free grade NADH (CAS No.: 606-68-98) Functional food and drink; Biomedical research and development Healthcare product; Diagnostic reagents NADP (CAS No.: 24292-60-2/1184-16-3) Raw materials for medicine or enzyme catalysis; Diagnostic reagents; In vitro diagnostic reagents (GR); Biomedical research and development S-NAD (CAS No.: 4090-29-3) Biochemical diagnostic reagents NR (CAS No.: 23111-00-4) Healthcare products; Cosmetics; Diagnostic reagent Natural products Ginsenoside Rh2(CAS No.:78214-33-2) Healthcare products; Cosmetics; Drink; Alcohol; Medicine; Functional food Ginsenoside Rg3(Cas No. : 38243-03-7) Salidroside (Cas No.: 10338-51-9) Healthcare products; Scientific research experiment; New drug development Stevia Sweetener (RD)(Cas No.: 63279-13-0 ) Food; Drink; Daily chemical industry; Brewing Raw materials for cosmetics Pro-Xylane (CAS No.: 439685-79-7) Cosmetics Erythrothioneine Cosmetics Dietary supplements L-Glutathione Reduced Healthcare products; Cosmetics Resveratrol Healthcare products; Cosmetics Phosphatidylserine Healthcare products; Biochemical diagnostic reagent Medicine and intermediate Ursodeoxycholic acid(CAS No.: 128-13-2) Healthcare products; Biochemical diagnostic reagent Chenodeoxycholic acid Healthcare products; Biochemical diagnostic reagent Cholic acid Healthcare products; Biochemical diagnostic reagents BONTAC profile Bontac Bio-Engineering (Shenzhen) Co., Ltd. (also referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales. There are six major series of product in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates. BONTAC is the pioneer of NMN industry. By virtue of the first whole-enzyme catalysis technology in China, BONTAC takes the industry lead in its niche field of coenzyme. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents.